Abstract:Rationale: Hyperlipidemia is a major risk factor of atherosclerosis and cardiovascular diseases (CVD). As a standard-of-care approach for hyperlipidemia, statins only reduce the risk of coronary artery disease by 20-40%, underscoring the importance of identifying molecular pathways for the design of drugs against this disorder. Alterations in microRNA (miRNA) expression have been reported in patients with hyperlipidemia and CVD. This study was designed to determine the mechanism of dysregulated miR-378a-3p under the status of hyperlipidemia and evaluate how miR-378a-3p regulates hepatic secretion of VLDL. Methods: Wild-type mice kept on a high fat diet were injected with miR-378a-3p inhibitor or a mini-circle expression system containing miR-378a precursor to study loss and gain-of functions of miR-378a-3p. Mice were treated with Triton WR1339 and S-35-methionine/cysteine to determine the effect of miR-378a-3p on hepatic secretion of VLDL. Database mining, luciferase assay, and ChIP (chromatin immunoprecipitation) were used to study the mechanism of dysregulated miR-378a-3p biogenesis. Results: miR-378a-3p expression is significantly increased in livers of hyperlipidemic mice. Sort1 (sortilin 1) was identified as a direct target of miR-378a-3p. By inhibiting the function of sortilin 1 as a transmembrane trafficking receptor, miR-378a-3p stabilized ApoB100 and promoted ApoB100 secretion in vitro. Liver-specific expression of miR-378a-3p stabilized ApoB100 and facilitated hepatic secretion of VLDL, which subsequently increased levels of VLDL/LDL cholesterol as well as triglycerides. In contrast, antagonizing miR-378a-3p using its inhibitor increased hepatic expression of Sort1 and reduced hepatic export of VLDL with its consequent effects of serum lipid levels. Additional knockdown of up-regulated Sort1 in livers of mice offset the effects of miR-378a-3p inhibitor, suggesting that Sort1 was indispensable for miR-378a-3p to promote secretion of VLDL and thereby high levels of circulating VLDL/LDL cholesterol and triglycerides. Furthermore, oncogenic E2F1 (E2F transcription factor 1) was identified as a transcriptional activator of miR-378a-3p. E2f1 knockdown, through reducing miR-378a-3p, impaired secretion of VLDL and reduced levels of VLDL/LDL cholesterol and triglycerides. Conclusions: This study defines a novel pathway of E2F1-miR-378a-3p-SORT1-ApoB100 that controls levels of circulating VLDL/LDL cholesterol and triglycerides by modulating degradation and secretion of ApoB100, and suggests the use of miR-378a-3p as a potential therapeutic target for dyslipidemia.

MicroRNA-185 modulates CYP7A1 mediated cholesterol-bile acid metabolism through post-transcriptional and post-translational regulation of FoxO1

Microrna-181A Represses Ox-Ldl-stimulated Inflammatory Response in Dendritic Cell by Targeting C-Fos

microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator.

Hepatic miR-378 modulates serum cholesterol levels by regulating hepatic bile acid synthesis

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production

MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux

MicroRNAs 185, 96, and 223 Repress Selective High-Density Lipoprotein Cholesterol Uptake Through Posttranscriptional Inhibition

MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice

MicroRNA-376b-3p ameliorates nonalcoholic fatty liver disease by targeting FGFR1 and regulating lipid oxidation in hepatocytes

The Effects of Mir-467B on Lipoprotein Lipase (LPL) Expression, Pro-Inflammatory Cytokine, Lipid Levels and Atherosclerotic Lesions in Apolipoprotein E Knockout Mice

MicroRNA-320b Modulates Cholesterol Efflux and Atherosclerosis

MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes

MicroRNA-27a/b regulates cellular cholesterol efflux, influx and esterification/hydrolysis in THP-1 macrophages.

MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice.

MicroRNA-379-5p Regulates Free Cholesterol Accumulation and Relieves Diet Induced-Liver Damage in Db/db Mice Via STAT1/HMGCS1 Axis

Activation of microRNA-378a-3p biogenesis promotes hepatic secretion of VLDL and hyperlipidemia by modulating ApoB100-Sortilin1 axis.

Visible-Light-Driven Zr-MOF/BiOBr Heterojunction for the Efficient Synchronous Removal of Hexavalent Chromium and Rhodamine B from Wastewater.

MicroRNA-19b Promotes Macrophage Cholesterol Accumulation and Aortic Atherosclerosis by Targeting ATP-binding Cassette Transporter A1.

Microrna-590 Inhibits Lipoprotein Lipase Expression And Prevents Atherosclerosis In Apoe Knockout Mice

Recent progress of microRNAs regulating cholesterol homeostasis

MicroRNA-33-5p inhibits cholesterol efflux in vascular endothelial cells by regulating citrate synthase and ATP-binding cassette transporter A1